FAM161A Antikörper (AA 301-400)
Kurzübersicht für FAM161A Antikörper (AA 301-400) (ABIN873165)
Target
Alle FAM161A Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 301-400
-
Kreuzreaktivität
- Human
-
Homologie
- Mouse,Rat,Dog
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human FAM161A
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- FAM161A (Family with Sequence Similarity 161, Member A (FAM161A))
-
Andere Bezeichnung
- Fam161a
-
Hintergrund
-
Synonyms: F161A_HUMAN, Fam161a, Family with sequence similarity 161, member A, FLJ13305, Hypothetical protein LOC84140, MGC129982, MGC129983, OTTHUMP00000201353, Protein FAM161A.
Background: Isoform 1 and isoform 3 are widely expressed with highest levels in retina and testis, with isoform 1 being the mot abundant in all tissues tested.Involvement in disease:Defects in FAM161A are the cause of retinitis pigmentosa type 28 (RP28) . A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.
Target
-